BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 29326002)

  • 1. Prevalence of adult Pompe disease in patients with proximal myopathic syndrome and undiagnosed muscle biopsy.
    Golsari A; Nasimzadah A; Thomalla G; Keller S; Gerloff C; Magnus T
    Neuromuscul Disord; 2018 Mar; 28(3):257-261. PubMed ID: 29326002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Late-onset Pompe disease is prevalent in unclassified limb-girdle muscular dystrophies.
    Preisler N; Lukacs Z; Vinge L; Madsen KL; Husu E; Hansen RS; Duno M; Andersen H; Laub M; Vissing J
    Mol Genet Metab; 2013 Nov; 110(3):287-9. PubMed ID: 24011652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is early detection of late-onset Pompe disease a pneumologist's affair? A lesson from an Italian screening study.
    Confalonieri M; Vitacca M; Scala R; Polverino M; Sabato E; Crescimanno G; Ceriana P; Antonaglia C; Siciliano G; Ring N; Zacchigna S; Salton F; Vianello A;
    Orphanet J Rare Dis; 2019 Mar; 14(1):62. PubMed ID: 30832705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vacuolated PAS-positive lymphocytes as an hallmark of Pompe disease and other myopathies related to impaired autophagy.
    Pascarella A; Terracciano C; Farina O; Lombardi L; Esposito T; Napolitano F; Franzese G; Panella G; Tuccillo F; la Marca G; Bernardini S; Boffo S; Giordano A; Di Iorio G; Melone MAB; Sampaolo S
    J Cell Physiol; 2018 Aug; 233(8):5829-5837. PubMed ID: 29215735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Late-onset Pompe disease: what is the prevalence of limb-girdle muscular weakness presentation?
    Lorenzoni PJ; Kay CSK; Higashi NS; D'Almeida V; Werneck LC; Scola RH
    Arq Neuropsiquiatr; 2018 Apr; 76(4):247-251. PubMed ID: 29742245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The frequency of late-onset Pompe disease in pediatric patients with limb-girdle muscle weakness and nonspecific hyperCKemia: A multicenter study.
    Ünver O; Hacıfazlıoğlu NE; Karatoprak E; Güneş AS; Sağer G; Kutlubay B; Sözen G; Saltık S; Yılmaz K; Kara B; Türkdoğan D
    Neuromuscul Disord; 2016 Nov; 26(11):796-800. PubMed ID: 27666774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LOPED study: looking for an early diagnosis in a late-onset Pompe disease high-risk population.
    Musumeci O; la Marca G; Spada M; Mondello S; Danesino C; Comi GP; Pegoraro E; Antonini G; Marrosu G; Liguori R; Morandi L; Moggio M; Massa R; Ravaglia S; Di Muzio A; Filosto M; Tonin P; Di Iorio G; Servidei S; Siciliano G; Angelini C; Mongini T; Toscano A;
    J Neurol Neurosurg Psychiatry; 2016 Jan; 87(1):5-11. PubMed ID: 25783438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted gene panel screening is an effective tool to identify undiagnosed late onset Pompe disease.
    Savarese M; Torella A; Musumeci O; Angelini C; Astrea G; Bello L; Bruno C; Comi GP; Di Fruscio G; Piluso G; Di Iorio G; Ergoli M; Esposito G; Fanin M; Farina O; Fiorillo C; Garofalo A; Giugliano T; Magri F; Minetti C; Moggio M; Passamano L; Pegoraro E; Picillo E; Sampaolo S; Santorelli FM; Semplicini C; Udd B; Toscano A; Politano L; Nigro V
    Neuromuscul Disord; 2018 Jul; 28(7):586-591. PubMed ID: 29880332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of Pompe disease in 3,076 patients with hyperCKemia and limb-girdle muscular weakness.
    Lukacs Z; Nieves Cobos P; Wenninger S; Willis TA; Guglieri M; Roberts M; Quinlivan R; Hilton-Jones D; Evangelista T; Zierz S; Schlotter-Weigel B; Walter MC; Reilich P; Klopstock T; Deschauer M; Straub V; Müller-Felber W; Schoser B
    Neurology; 2016 Jul; 87(3):295-8. PubMed ID: 27170567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reevaluating Muscle Biopsies in the Diagnosis of Pompe Disease: A Corroborative Report.
    Genge A; Campbell N
    Can J Neurol Sci; 2016 Jul; 43(4):561-6. PubMed ID: 27039993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adult glycogenosis type II (Pompe's disease): morphological abnormalities in muscle and skin biopsies compared with acid alpha-glucosidase activity.
    Wierzba-Bobrowicz T; Lewandowska E; Lugowska A; Rola R; Stepień T; Ryglewicz D; Pasennik E
    Folia Neuropathol; 2007; 45(4):179-86. PubMed ID: 18176891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of short-to-long term enzyme replacement therapy (ERT) on skeletal muscle tissue in late onset Pompe disease (LOPD).
    Ripolone M; Violano R; Ronchi D; Mondello S; Nascimbeni A; Colombo I; Fagiolari G; Bordoni A; Fortunato F; Lucchini V; Saredi S; Filosto M; Musumeci O; Tonin P; Mongini T; Previtali S; Morandi L; Angelini C; Mora M; Sandri M; Sciacco M; Toscano A; Comi GP; Moggio M
    Neuropathol Appl Neurobiol; 2018 Aug; 44(5):449-462. PubMed ID: 28574618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective screening of late-onset Pompe disease (LOPD) in patients with non-diagnostic muscle biopsies.
    Meznaric M; Fumic K; Leonardis L
    J Clin Pathol; 2019 Jul; 72(7):468-472. PubMed ID: 30878973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A database for screening and registering late onset Pompe disease in Turkey.
    Gokyigit MC; Ekmekci H; Durmus H; Karlı N; Koseoglu E; Aysal F; Kotan D; Ali A; Koytak PK; Karasoy H; Yaman A; Sengun İS; Sayin R; Tiftikcioglu BI; Soysal A; Tutkavul K; Bayrak AO; Kısabay A; Elci MA; Yayla V; Yılmaz İA; Ozdamar SE; Erdogan C; Tasdemir N; Serdaroglu Oflazer P;
    Neuromuscul Disord; 2018 Mar; 28(3):262-267. PubMed ID: 29395671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening for late-onset Pompe disease in Poland.
    Jastrzębska A; Potulska-Chromik A; Łusakowska A; Jastrzębski M; Lipowska M; Kierdaszuk B; Kamińska A; Kostera-Pruszczyk A
    Acta Neurol Scand; 2019 Oct; 140(4):239-243. PubMed ID: 31125121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of GAA variants through whole exome sequencing targeted to a cohort of 606 patients with unexplained limb-girdle muscle weakness.
    Johnson K; Töpf A; Bertoli M; Phillips L; Claeys KG; Stojanovic VR; Perić S; Hahn A; Maddison P; Akay E; Bastian AE; Łusakowska A; Kostera-Pruszczyk A; Lek M; Xu L; MacArthur DG; Straub V
    Orphanet J Rare Dis; 2017 Nov; 12(1):173. PubMed ID: 29149851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening for late-onset Pompe disease in western Denmark.
    Hansen JS; Pedersen EG; Gaist D; Bach FW; Vilholm OJ; Sandal B; Weitemeyer L; Nielsen K; Schlesinger FE; Preisler N; Vissing J; Andersen H
    Acta Neurol Scand; 2018 Jan; 137(1):85-90. PubMed ID: 28832912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Latin American experience with a next generation sequencing genetic panel for recessive limb-girdle muscular weakness and Pompe disease.
    Bevilacqua JA; Guecaimburu Ehuletche MDR; Perna A; Dubrovsky A; Franca MC; Vargas S; Hegde M; Claeys KG; Straub V; Daba N; Faria R; Periquet M; Sparks S; Thibault N; Araujo R
    Orphanet J Rare Dis; 2020 Jan; 15(1):11. PubMed ID: 31931849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Remarkably low fibroblast acid α-glucosidase activity in three adults with Pompe disease.
    Wens SC; Kroos MA; de Vries JM; Hoogeveen-Westerveld M; Wijgerde MG; van Doorn PA; van der Ploeg AT; Reuser AJ
    Mol Genet Metab; 2012 Nov; 107(3):485-9. PubMed ID: 23000108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An integrative correlation of myopathology, phenotype and genotype in late onset Pompe disease.
    Kulessa M; Weyer-Menkhoff I; Viergutz L; Kornblum C; Claeys KG; Schneider I; Plöckinger U; Young P; Boentert M; Vielhaber S; Mawrin C; Bergmann M; Weis J; Ziagaki A; Stenzel W; Deschauer M; Nolte D; Hahn A; Schoser B; Schänzer A
    Neuropathol Appl Neurobiol; 2020 Jun; 46(4):359-374. PubMed ID: 31545528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.